Bearing in mind that AChE and butyrylcholinesterase (BuChE) play a key role in the regulation of acetylcholine levels in the brain, and their inhibition can lead to increased acetylcholine levels that can have potential therapeutic benefits in certain neurodegenerative diseases, such as AD, the anticholinergic ability of the compounds was studied by evaluating their activity to inhibit in vitro the two metabolic enzymes of acetylcholine, AChE and BuChE, as a means to check whether they may serve as potential neuroprotectors. Here, ACHE is linked to neurodegenerative disease.